Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Front Pharmacol 2022;13:998816
The SELECT cardiovascular trial shut down a year early because results were so impressive, says Dr
HOLST: Yeah, so the way I would like to put it is there are two major areas of effects of GLP-1 that we really haven't talked about, and one is the vascular system
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved in the UK for type 2 diabetes management and for weight management in adults with obesity or overweight with weight-related comorbidities
Across multiple national and multinational healthcare databases, GLP-1 use was associated with lower rates of colorectal cancer compared with non-use and with other antidiabetic therapies, including insulin and sulfonylureas
